Literature DB >> 23200410

Outcomes of unselected patients with pathologic T3N0 rectal cancer.

Hagen Kennecke1, Howard Lim, Ryan Woods, Colleen E McGahan, John Hay, Manoj J Raval, Balvinder Johal.   

Abstract

BACKGROUND AND
PURPOSE: This study compares the outcomes of patients with pathological (p) T3N0 rectal cancer treated with surgery alone (S), surgery and radiation (SR) or surgery, radiation and chemotherapy (SRC), in a population based setting. MATERIALS: Three hundred and seven patients with operable, macroscopically resected pT3N0 rectal cancer referred to the BC Cancer Agency between 2000 and 2004 were segregated by treatment type: S (n=65), SR (n=97) and SRC (n=145). Patient characteristics, 5-year locoregional recurrence (LRR) and disease-specific survival (DSS) were compared between treatment cohorts.
RESULTS: Median age differed significantly between S, SR and SRC patient cohorts: 76, 72 and 64 years respectively. Five-year LRR differed by treatment group, with 29% for S, 6.3% for SR and 3.84% for SRC patients. DSS was superior in SRC compared to S patients (hazard ratio=0.31 [0.17, 0.60]). Co-morbidities and patient preference were most common reasons for omission of radiation.
CONCLUSIONS: Unselected patients with pT3N0 rectal cancer not treated with peri-operative radiation experience a high rate of LRR and reduced DSS in comparison to patients treated with bimodality and trimodality therapies. Advanced age is significantly associated with omission of therapy in patients with early stage rectal cancer.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23200410     DOI: 10.1016/j.radonc.2012.09.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  5 in total

1.  Chemo-Radiation After Upfront Rectal Resections-a Clinical Dilemma.

Authors:  A Saklani; P Sugoor; M Bhandare; S Jatal; A Desouza; V Ostwal
Journal:  Indian J Surg Oncol       Date:  2018-08-18

2.  Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.

Authors:  Luca Sorrentino; Marcello Guaglio; Luigi Battaglia; Giuliano Bonfanti; Marco Vitellaro; Alessandro Cesa Bianchi; Massimo Milione; Filiberto Belli
Journal:  Int J Colorectal Dis       Date:  2019-11-18       Impact factor: 2.571

3.  Role of postoperative radiotherapy in pT3N0 rectal cancer: A risk-stratification system based on population analyses.

Authors:  Yun-Xia Huang; Yan-Zong Lin; Jin-Luan Li; Xue-Qing Zhang; Li-Rui Tang; Qing-Yang Zhuang; Fei-Fei Lin; Xi-Jin Lin; Jun-Xin Wu
Journal:  Cancer Med       Date:  2019-02-04       Impact factor: 4.452

4.  Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis.

Authors:  Michael Jonathan Kucharczyk; Andrew Bang; Michael C Tjong; Stefania Papatheodorou; Jesus C Fabregas
Journal:  Oncotarget       Date:  2022-10-08

5.  Radiotherapy for stage IIA rectal cancer may not benefit all.

Authors:  Xiang Hu; Ya-Qi Li; Qing-Guo Li; Yan-Lei Ma; Jun-Jie Peng; San-Jun Cai
Journal:  Oncotarget       Date:  2017-07-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.